Disusun Oleh :
1102012222
FAKULTAS KEDOKTERAN
UNIVERSITAS YARSI
Januari 2018
Skenario
Pertanyaan
Apakah pemberian obat levostati lebih efektif dalam mencegah terjadinya Dengue
Fever dibandingkan dengan tidak diberikan obat ?
PICO
I : Obat Levostatin
C : Plasebo
Website : http://www.nejm.org/doi/full/10.1056/NEJMoa1411037
1. Lovastatin for the Treatment of Adult Patients With Dengue: A Randomized, Double-
Blind, Placebo Controlled Trial
2. Efficacy of a tetravalent dengue vaccine in children in Latin America.
3. Extended Evaluation of Virological, Immunological and Pharmacokinetic Endpoints
of CELADEN: A Randomized, Placebo-Controlled Trial of Celgosivir in Dengue
Fever Patients.
“Lovastatin for the Treatment of Adult Patients With Dengue: A Randomized, Double-Blind,
Placebo Controlled Trial”.
Nama pengarang :
James Whitehorn, Nguyen Thuy Hang, Marcel Wolbers, Chau Van Vinh Nguyen, Nguyen
Thanh Truong, Cameron P. Simmons, Lam Phung Khanh, Luong Thi Hue Tai, and Bridget
Wills, Duong Thi Hue Kien, Nguyen Thi Cam Huong, Nguyen Than Ha Quyen, Vo Thanh
Nhon, Nguyen Thi Thanh Tran, Ta Van Tram, Jeremy Farrar.
Sumber Jurnal :
Abstract
Background.
Dengue endangers billions of people in the tropical world, yet no therapeutic is currently
available. In part, the severe manifestations of dengue reflect inflammatory processes
affecting the vascular endothelium. In addition to lipid lowering, statins have pleiotropic
effects that improve endothelial function, and epidemiological studies suggest that outcomes
from a range of acute inflammatory syndromes are improved in patients already on statin
therapy.
Methods.
Following satisfactory review of a short pilot phase (40 mg lovastatin vs placebo in 30 cases),
we performed a randomized, double-blind, placebo-controlled trial of 5 days of 80 mg
lovastatin vs placebo in 300 Vietnamese adults with a positive dengue NS1 rapid test
presenting within 72 hours of fever onset. The primary outcome was safety. Secondary
outcomes included comparisons of disease progression rates, fever clearance times, and
measures of plasma viremia and quality of life between the treatment arms.
Results.
Adverse events occurred with similar frequency in both groups (97/151 [64%] placebo vs
82/149 [55%] lovastatin; P = .13), and were in keeping with the characteristic clinical and
laboratory features of acute dengue. We also observed no differencein serious adverse events
or any of the secondary outcome measures.
Conclusions.
We found lovastatin to be safe and well tolerated in adults with dengue. However, although
the study was not powered to address efficacy, we found no evidence of a beneficial effect on
any of the clinical manifestations or on dengue viremia. Continuing established statin therapy
in patients who develop dengue is safe.
0,2475 0,2304
=0,09 (±1,96√ + )
149 151
8,24+11,26
=0,09 (±1,96√ )
4752
= 0,09 ± 1,96 x 0,06
= 0,09 ± 0,12
= 0,21 – (-0,03) = 0,24
95% CI NNT Mengurangi komplikasi penyakit Dengue
1 1
95% CI NNT = 95% 𝐶𝐼 𝐴𝑅𝑅 = 0,24
= 4,16
III. APPLICABILITY: Apakah hasil tersebut akan membantu saya dalam melayani
pasien?
1. Apakah hasil ini dapat diterapkan untuk pasien saya?
Ya,hasil penelitian ini dapat diterapkan pada pasien saya karena pasien saya
terdiagnosis dengue fever.